Thomas P. Stossel (September 10, 1941 – September 29, 2019) was an American hematologist, inventor, medical researcher, and writer, who discovered gelsolin and invented the BioAegis technology estate. He was also a professor emeritus of medicine at Harvard Medical School and a professor emeritus of clinical research at the American Cancer Society. He was Chief Scientific Advisor to BioAegis Therapeutics Inc., a clinical-stage biotech company developing a non-immunosuppressive anti-inflammatory with the potential to address a wide range of infectious, inflammatory, and degenerative diseases.
Contents
Education and career
Stossel majored in English at Princeton University, graduating in 1963. He went on to Harvard Medical School. He completed his internship and residency in internal medicine at the Massachusetts General Hospital in Boston and was a staff associate at the National Heart Institute, after which he received training in hematology at Boston Children's and Peter Bent Brigham Hospitals. He was chief of hematology-oncology at the Massachusetts General Hospital (1976–1991), head of experimental medicine at Brigham and Women's Hospital (1991–1998), and co-director of hematology (1998–2006) and translational medicine (2011–2014) at that institution. He served on the scientific advisory boards of Biogen, Inc. (1997–2002), Dyax, Inc. (1991–2001), and has been a director of Velico Medical Inc. since 2000. He was president of the American Society for Clinical Investigation and of the American Society of Hematology, served on the Lasker Awards' jury, and served as editor-in-chief of The Journal of Clinical Investigation and of Current Opinion in Hematology. Until his death, he was a member of the scientific advisory board of the Forsyth Dental Institute and a trustee of the American Council on Science and Health.